Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
Smolen JS, Sebba A, Ruderman EM, Schulze-Koops H, Sapin C, Gellett AM, Sprabery AT, Li L, de la Torre I, Gallo G, Liu-Leage S, Pillai S, Reis P, Nash P. Smolen JS, et al. Rheumatol Ther. 2020 Dec;7(4):1021-1035. doi: 10.1007/s40744-020-00250-3. Epub 2020 Nov 16. Rheumatol Ther. 2020. PMID: 33200394 Free PMC article.
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.
Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J. Stamm TA, et al. Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z. Arthritis Res Ther. 2018. PMID: 30092827 Free PMC article. Clinical Trial.
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
Jaworski J, Matucci-Cerinic M, Schulze-Koops H, Buch MH, Kucharz EJ, Allanore Y, Kavanaugh A, Young P, Babic G. Jaworski J, et al. Arthritis Res Ther. 2019 May 28;21(1):130. doi: 10.1186/s13075-019-1907-x. Arthritis Res Ther. 2019. PMID: 31138316 Free PMC article. Clinical Trial.
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P. Smolen JS, et al. Ann Rheum Dis. 2020 Oct;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13. Ann Rheum Dis. 2020. PMID: 32660977 Free PMC article. Clinical Trial.
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, Strangfeld A, Gossec L, Carmona L, Mateus EF, Lawson-Tovey S, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Pons-Estel GJ, Isnardi CA, Berbotto GA, Hsu TY, D'Silva KM, Patel NJ, Kearsley-Fleet L, Schäfer M, Ribeiro SLE, Al Emadi S, Tidblad L, Scirè CA, Raffeiner B, Thomas T, Flipo RM, Avouac J, Seror R, Bernardes M, Cunha MM, Hasseli R, Schulze-Koops H, Müller-Ladner U, Specker C, Souza VA, Mota LMHD, Gomides APM, Dieudé P, Nikiphorou E, Kronzer VL, Singh N, Ugarte-Gil MF, Wallace B, Akpabio A, Thomas R, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Yazdany J; COVID-19 Global Rheumatology Alliance. Sparks JA, et al. Ann Rheum Dis. 2021 Sep;80(9):1137-1146. doi: 10.1136/annrheumdis-2021-220418. Epub 2021 May 28. Ann Rheum Dis. 2021. PMID: 34049860 Free PMC article.
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study.
Izadi Z, Gianfrancesco MA, Schmajuk G, Jacobsohn L, Katz P, Rush S, Ja C, Taylor T, Shidara K, Danila MI, Wysham KD, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schaefer M, Al-Emadi S, Sparks JA, Hsu TY, Patel NJ, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada MO, Ugarte-Gil MF, Ljung L, Scirè CA, Carrara G, Hachulla E, Richez C, Cacoub P, Thomas T, Santos MJ, Bernardes M, Hasseli R, Regierer A, Schulze-Koops H, Müller-Ladner U, Pons-Estel G, Tanten R, Nieto RE, Pisoni CN, Tissera YS, Xavier R, Lopes Marques CD, Pileggi GCS, Robinson PC, Machado PM, Sirotich E, Liew JW, Hausmann JS, Sufka P, Grainger R, Bhana S, Gore-Massy M, Wallace ZS, Yazdany J; COVID-19 Global Rheumatology Alliance Registry. Izadi Z, et al. Lancet Rheumatol. 2022 Sep;4(9):e603-e613. doi: 10.1016/S2665-9913(22)00192-8. Epub 2022 Jul 25. Lancet Rheumatol. 2022. PMID: 35909441 Free PMC article.
307 results